SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (135)12/24/1996 1:34:00 AM
From: jay silberman   of 6136
 
Henry,

AGPH itself was not the only thing on CNBC - Peter Johnson was, too, on "Business Insiders". Notable commments:

1. He expects FDA approval in 2-3 months;

2. Sees the PI market (in the US) as $1-5B. There are currently 850,000 people infected; only 10% are getting PIs, for which they are now expending $0.5B.

Here's how IBD wrote up today's news. Nice to see them mention the children issue:

Agouron Pharmaceuticals Inc. soared 5 1/2 to 67 3/4, a new closing high on double its average trade. The
company has filed for FDA approval to market its Viracept anti-Aids drug for adults and children. Several
companies have applied for permission to market similar drugs, but Agouron's the first to modify its product for
children. It also wasn't expected to file until the first quarter.

When used in combination with other Aids drugs, Viracept's been found to reduce the HIV virus to imperceptible
levels. The stock's doubled in a year.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News